血管新生是从已有的脉管系统形成新的血管并受严格调控的多步骤过程，最新研究结果表明血管新生可能是门静脉高压发生发展的新机制，血栓素A2（TXA2）可以调节血管新生，我们前期研究表明长链非编码RNA lncRNA-RP11的表达与小肠TXA2含量和微血管密度呈线性相关，提示我们lncRNA-RP11可能通过调节TXA2调控肝外血管新生。本项目拟从肝外血管新生这个全新的角度阐释门静脉高压发生发展的机制，并深入研究TXA2在肝外血管新生中作用及其分子机制；然后希望通过抑制lncRNA-RP11调节TXA2从而抑制肝外血管新生、缓解门静脉高压，并对lncRNA-RP11调节TXA2的分子机制进行深入的研究, 以期能够从分子、细胞水平发现肝外血管新生的规律，为门静脉高压的临床治疗策略提供新思路。

Angiogenesis refers to the development of new blood vessels from the existing vasculature. Recent data suggest that angiogenesis is associated with fibrosis and portal hypertension. Thromboxane A2 (TXA2) is a key regulation molecule of angiogenesis. It has been established in our previous study that expression of long non-coding RNA lncRNA-RP11 is correlation with the concentration of TXA2 and micro vascular density in intestine, which indicated that lncRNA-RP11 might regulation of extrahepatic angiogenesis via TXA2. In the present project, the angiogenic effect of TXA2 on the development of liver cirrhosis and portal hypertension will be studied, and the molecular mechanism of TXA2 on extrahepatic angiogenesis will also be investigated. It will be demonstrated that lncRNA-RP11 regulation of extrahepatic angiogenesis of liver cirrhosis and portal hypertension by stimulation of thromboxane A2. Additionally, the accurate molecular mechanism will also serve as investigated, which serve us a new idea for clinical treatment of portal hypertension.